{{Rsnum
|rsid=11572080
|Gene=CYP2C8
|Chromosome=10
|position=96827030
|Orientation=minus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.06474
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.8 | 20.2 | 77.1
| HCB | 0.0 | 2.2 | 97.8
| JPT | 0.0 | 0.0 | 0.0
| YRI | 0.0 | 0.0 | 0.0
| ASW | 0.0 | 8.8 | 91.2
| CHB | 0.0 | 2.2 | 97.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 7.1 | 92.9
| LWK | 0.0 | 0.0 | 0.0
| MEX | 1.8 | 16.1 | 82.1
| MKK | 0.0 | 5.4 | 94.6
| TSI | 3.0 | 19.8 | 77.2
| HapMapRevision=28
}}[[CYP2C8]] SNP, defining the CYP2C8*3 allele (along with [[rs10509681]]).

Individuals carrying this SNP may show increased risk of developing acute gastrointestinal bleeding during the use of [[NSAID]]s that are CYP2C8 or CYP2C9 substrates, such as [[aceclofenac]], [[celecoxib]], [[diclofenac]], [[ibuprofen]], [[indomethazine]], [[lornoxicam]], [[meloxicam]], [[naproxen]], [[piroxicam]], [[tenoxicam]] and [[valdecoxib]].{{PMID|19422321}}

{{PharmGKB
|RSID=rs11572080
|Name_s=rs11572080 G>A; CYP2C8*3; R139K
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:20212519
|Annotation=Risk or phenotype-associated allele: A. Phenotype: This variant was associated with increased risk for neurotoxicity with paclitaxel treatment. Study size: 132. Study population/ethnicity: Patients with Neoplasms receiving paclitaxel; Spain. Significance metric(s): HR = 1.54 (0.96-2.47); p = 0.072. Type of association: PK; TOX.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Drug Toxicity; Neurotoxicity Syndromes
|Curation Level=Curated
|PharmGKB Accession ID=PA165291995
}}

{{PharmGKB
|RSID=rs11572080
|Name_s=CYP2C8: R139K; G416A
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:11668219
|Annotation=The variant is part of the CYP2C8*3 allele. In in vitro studies, the recombinant expressed CYP2C8*3 exhibits markedly impaired metabolism of paclitaxel and arachidonic acid.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161660768
}}

{{PharmGKB
|RSID=rs11572080
|Name_s=CYP2C8: R139K; G416A; CYP2C8*3
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:14534525; PubMed ID:17178266
|Annotation=Different literature sources show a discrepancy between several in vitro findings describing a lower activity of the CYP2C8*3 variant and in vivo findings showing higher oral clearance in *3 allele carriers at last for some substrates ofCYP2C8. A study on healthy volunteers administered with repaglinide found that the CYP2C8*3 variant allele was associated with reduced plasma conentrations of repaglinde. Another study showed that subjects carrying the CYP2C8*3allele had a lower rosiglitazone plasma concentartion.
|Drugs=repaglinide; rosiglitazone
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161660864
}}

{{PharmGKB
|RSID=rs11572080
|Name_s=CYP2C8: R139K; G416A; CYP2C8*3
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18855526
|Annotation=CYP2C8*3 has no detectable amodiaquine metabolism activity in vitro.
|Drugs=amodiaquine
|Drug Classes=
|Diseases=Malaria
|Curation Level=Curated
|PharmGKB Accession ID=PA162360172
}}

{{PharmGKB
|RSID=rs11572080
|Name_s=CYP2C8: R139K; G416A; CYP2C8*3
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17963417
|Annotation=CYP2C8*3 allele (containing Arg139Lys and Lys399Arg) is associated with increased the clearance of meglitinides.
|Drugs=
|Drug Classes=MEGLITINIDES
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA162361001
}}

{{PharmGKB
|RSID=rs11572080
|Name_s=CYP2C8: R139K; G416A; CYP2C8*3
|Gene_s=CYP2C8
|Feature=Exon/NonSyn
|Evidence=PubMed ID:14646690
|Annotation=Risk or phenotype-associated allele: A. Phenotype: In woman, the risk of acute myocardial infarction (AMI) tended to be higher for subjects carrying the CYP2C8*3*3 genotype versus *1*1 (OR = 1.9). The CYP2C8*3 variants are 416G>A (rs10509681) and 1196A>G (rs11572080). Tested in all subjects, the risk of AMI was also higher in individuals carrying the CYP2C8*3 allele (*3*3; *1*3 versus*1*1) [1.2 (1.0-1.5), P = 0.07]. Study size: 1172 AMI patients and 1503 control subjects. Study population: Caucasian.
|Drugs=
|Drug Classes=
|Diseases=Myocardial Infarction
|Curation Level=Curated
|PharmGKB Accession ID=PA162361003
}}

{{PMID Auto
|PMID=16385451
|Title=A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.
|OA=1
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=18303964
|Title=Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
}}

{{PMID Auto
|PMID=18769365
|Title=Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
|OA=1
}}

{{PMID Auto
|PMID=19761371
|Title=Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
|OA=1
}}

{{PMID Auto
|PMID=20808793
|Title=Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?
|OA=1
}}

{{GET Evidence
|gene=CYP2C8
|aa_change=Arg139Lys
|aa_change_short=R139K
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11572080
|overall_frequency_n=931
|overall_frequency_d=10758
|overall_frequency=0.0865403
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=5
|n_articles_annotated=5
|in_pharmgkb=Y
|pph2_score=0.015
|nblosum100=-3
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23267857
|Title=CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease
}}

{{PMID Auto
|PMID=23420707
|Title=Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{PMID Auto
|PMID=23426382
|Title=The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}